^
    3d
    FAERS based pharmacovigilance study and network pharmacology analysis of Lutathera and Pluvicto. (PubMed, Appl Radiat Isot)
    This FAERS analysis characterizes agent-specific safety profiles, informing pharmacovigilance strategies. Mechanistic profiling of adverse drug reactions optimizes evidence-based treatment, enhancing medication safety and refining benefit-risk profiles in clinical practice.
    Journal • Adverse events
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • SSTR (Somatostatin Receptor)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Lutathera (lutetium Lu 177 dotatate)
    4d
    Radiolabeled cyclic peptides in precision oncology: Current advances and future perspectives. (PubMed, J Control Release)
    In recent years, the regulatory approval of radiopharmaceuticals such as [177Lu]Lu-DOTATATE and [177Lu]Lu-PSMA-617, alongside their diagnostic counterparts [68Ga]Ga-DOTATATE and [68Ga]Ga-PSMA-11, has propelled theranostics into the clinical mainstream, marking a transformative shift in nuclear medicine and precision oncology...With their molecular precision, structural versatility, and therapeutic adaptability, cyclic peptides are positioned at the forefront of next-generation radiopharmaceutical development. As the field continues to evolve toward increasingly personalized and molecularly targeted cancer therapies, radiolabeled cyclic peptides are poised to play a pivotal role in redefining the future landscape of radiotherapy.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    SSTR (Somatostatin Receptor)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    5d
    [177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study. (PubMed, Lancet Oncol)
    Multicycle [177Lu]Lu-PSMA-617 and pembrolizumab showed encouraging activity with manageable toxicity that was consistent with [177Lu]Lu-PSMA-617 or pembrolizumab, and the combination might provide durable clinical benefit in a subset of patients.
    P1/2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    Keytruda (pembrolizumab) • docetaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    6d
    A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=130, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    6d
    A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC (clinicaltrials.gov)
    P1/2, N=123, Recruiting, Novartis Pharmaceuticals | N=73 --> 123
    Enrollment change • Trial initiation date
    |
    Xtandi (enzalutamide) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    7d
    Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Weill Medical College of Cornell University | Suspended --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=48 --> 20 | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2026 --> Dec 2027
    Enrollment closed • Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    CELLSEARCH®
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    7d
    PAnTHA: First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=198, Recruiting, Bayer | N=73 --> 198 | Trial completion date: May 2031 --> May 2032 | Trial primary completion date: Jun 2027 --> Nov 2028
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    FOLH1 positive
    15d
    177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, University of California, San Francisco | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    18d
    PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan (clinicaltrials.gov)
    P=N/A, N=753, Not yet recruiting, Novartis Pharmaceuticals
    New trial
    |
    FOLH1 positive
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    21d
    A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients (clinicaltrials.gov)
    P=N/A, N=1247, Completed, Novartis Pharmaceuticals
    New trial • Real-world evidence
    |
    carboplatin • docetaxel • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Provenge (sipuleucel-T)
    22d
    Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan (clinicaltrials.gov)
    P2, N=87, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    25d
    Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial (clinicaltrials.gov)
    P2, N=40, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)